INS and Hypoglycemia: Exogenous insulin or sulphonylurea (SU)-based therapies, while valuable in reducing hyperglycaemia, continue to act even after an ideal glucose concentration has been met and therefore pose the risk of over-correction and hypoglycaemia [2].